<DOC>
	<DOCNO>NCT03045523</DOCNO>
	<brief_summary>This clinical study phase IIa , multi-center , randomize , double-blind , placebo-controlled , parallel group study evaluate two dos orally administer GLPG2222 adult subject confirm diagnosis CF harbour one F508del CFTR mutation second gating ( class III ) mutation stable treatment ivacaftor . Up 35 evaluable subject plan include study . Eligible subject must stable treatment physician prescribe ivacaftor ( Kalydeco® ) least 28 day baseline visit . They randomize 2:2:1 ratio receive one two active dos GLPG2222 ( 150 mg q.d . 300 mg q.d . ) placebo q.d . administer 29 day . Subjects study minimum 6 week maximum 10 week , screen follow-up visit .</brief_summary>
	<brief_title>A Study Evaluate GLPG2222 Ivacaftor-treated Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Male female subject ≥ 18 year age , day signing Informed Consent Form ( ICF ) . 2 . A confirmed clinical diagnosis CF . 3 . One F508del mutation one allele CFTR gene , gate ( class III ) mutation ( one following : G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R ) 2nd allele CFTR gene ( document subject 's medical record CF registry ) . 4 . Weight ≥ 40 kg . 5 . Stable concomitant treatment least 4 week ( 28 day ) prior baseline ( include physician prescribe ivacaftor ( Kalydeco® ) 150 mg b.i.d. ) . 6 . Forced expiratory volume 1 second ( FEV1 ) ≥ 40 % predict normal age , gender height screening ( pre postbronchodilator ) . 1 . History clinically meaningful unstable uncontrolled chronic disease make subject unsuitable inclusion study opinion investigator . 2 . Unstable pulmonary status respiratory tract infection ( include rhinosinusitis ) require change therapy within 4 week baseline . 3 . Need supplemental oxygen day , &gt; 2 liter per minute ( LPM ) sleeping . 4 . History hepatic cirrhosis portal hypertension ( e.g. , signs/symptoms splenomegaly , esophageal varix , etc ) . 5 . Abnormal liver function test screening ; define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) and/or alkaline phosphatase and/or total bilirubin ( &gt; 1.5 time ULN ( CTCAE Grade 2 ) and/or gammaglutamyl transferase ( GGT ) ≥ 3x upper limit normal ( ULN ) , and/or total bilirubin ( &gt; 1.5 time ULN ( CTCAE Grade 2 ) . 6 . Estimated creatinine clearance &lt; 60mL/min use CockroftGault formula screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>